Harvard Apparatus Regenerative Technology, Inc. (HRGN) — SEC Financial Statements & Analysis

Harvard Apparatus Regenerative Technology, Inc. (HRGN) is a surgical & medical instruments & apparatus company, incorporated in DE. Harvard Apparatus Regenerative Technology, Inc. trades on OTC as: HRGN. Harvard Apparatus Regenerative Technology, Inc. (HRGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Harvard Apparatus Regenerative Technology, Inc. carries a market cap of $22.50M, a P/E ratio of -3.37x, a P/B ratio of -16.32x, a P/S ratio of 22.92x, an enterprise value of $22.70M, and an EV/EBITDA multiple of -3.38x. On profitability, it posts a gross margin of 7.54%, an operating margin of -683.30%, a net margin of -680.55%, a Return on Equity (ROE) of 2162.78%, a Return on Assets (ROA) of -349.71%, and a Return on Invested Capital (ROIC) of -2624.61%. Per share, it reports EPS of $-0.38, diluted EPS of $-0.54, free cash flow per share of $-0.21, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 44.62% year-over-year, net income growth of -0.04% year-over-year, and EPS growth of -9.49% year-over-year. On the balance sheet, it maintains a current ratio of 0.26x, a quick ratio of 0.15x, working capital of $-2.25M, a debt-to-equity ratio of -2.22x, a debt ratio of 1.82, an interest coverage ratio of -516.15x, free cash flow of $-3.63M (TTM), and net debt of $195.00K. Figures sourced from SEC EDGAR.

Market Cap

$22.50M

P/E TTM

-3.37x

EPS TTM

$-0.38

P/B TTM

-16.32x

ROE TTM

2162.78%

ROA TTM

-349.71%

Debt To Equity

-2.22x

Free Cash Flow TTM

$-3.63M

Net Revenue TTM Growth 1Y

44.62%

Data as of 2026-06-30 · Source: SEC EDGAR